FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF
THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of October, 2005

 

SkyePharma PLC


(Translation of registrant's name into English)

 

SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England


(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.

Form 20-F X      Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes         No X

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- _______


 



For immediate release                                                                         6 October 2005



                                                     SkyePharma PLC ("the Company")

                                               Notification of Major Interest in Shares

In  accordance  with the Companies  Act 1985 (as amended) the Company was informed by Fidelity  Investments  on 6 October 2005 that FMR
Corp and its direct and indirect subsidiaries and Fidelity International Limited and its direct and indirect  subsidiaries,  both being
non-beneficial  holders  ("Fidelity"),  had decreased  their holding by 4,250,091  ordinary  shares since their last filing on 31 March
2005.  Fidelity's revised holding amounts to 79,902,498 ordinary shares of 10p each,  representing 12.7% of the issued share capital of
the Company.

                                                               - ends -



END

 

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

                                                                  SkyePharma PLC

                                                                      By: /s/ Douglas Parkhill

                                                                       Name: Douglas Parkhill
                                                                          Title: Company Secretary

Date:   October 6, 2005